

**HYPERLIPIDAEMIA EDUCATION AND RESEARCH
TRUST UK**

(A Company Limited by Guarantee)

ANNUAL REPORT AND FINANCIAL STATEMENTS

FOR THE YEAR ENDED 30 APRIL 2005

**Company No: 2631049
Registered in England and Wales**

HYPERLIPIDAEMIA EDUCATION AND RESEARCH TRUST UK

(A Company Limited by Guarantee)

CONTENTS

	Pages
Directors and advisors	1
Directors' report	2 - 11
Auditors' report	12
Consolidated statement of financial activities	13
Statement of total recognised gains and losses	14
Consolidated balance sheet	15
Company balance sheet	16
Notes to the financial statements	17 - 24

HYPERLIPIDAEMIA EDUCATION AND RESEARCH TRUST UK

(A Company Limited by Guarantee)

DIRECTORS AND ADVISORS

FOR THE YEAR ENDED 30 APRIL 2005

Chairman:	Dr J P D Reckless	
Directors:	Mrs D Davies	(Appointed 2 December 2004)
	Mrs Y Dumsday	
	Mr R B Edwards FCA	
	Dr E A Hughes	
	Mr E A Lazarus	
	Dr M I Mackness	(Resigned 1 July 2004)
	Dr J M Morrell	(Resigned 1 July 2004)
	Professor A Neil	(Appointed 2 December 2004)
	Dr R D G Neely	
	Professor N Sattar	
	Dr F C Sivers	
	Mr A R Smith	(Resigned 1 July 2004)
	Dr A S Wierzbicki	
	Dr J W Wright	
Company Secretary:	Mr M S Livingston	
Registered Office:	7 North Road Maidenhead Berkshire SL6 1PE	
Auditors:	Messrs Rothman Pantall & Co Fryern House 125 Winchester Road Chandlers Ford Hampshire SO53 2DR	
Bankers:	Natwest Bank plc 66 High Street Maidenhead Berkshire SL6 1QA	

Registered as a charity with the Charity Commissioners. Number 1003904.

HYPERLIPIDAEMIA EDUCATION AND RESEARCH TRUST UK

(A Company Limited by Guarantee)

DIRECTORS' REPORT

The Directors have pleasure in presenting their report and financial statements for the year ended 30 April 2005. The financial statements have been prepared in accordance with the accounting policies set out on pages 17 and 18 and comply with the Charity's governing document, current statutory requirements and applicable law.

STATUS

The Charity is constituted as a company limited by guarantee not having share capital and is registered by the Charities Commission, number 1003904, under the Charities Act. The company's registration number is 2631049.

ADDRESS

The registered address of the Charity together with the names and addresses of the Charity's auditors and bankers are given on page 1 of the Annual Report.

PRINCIPAL AIMS AND ACTIVITIES

The Company was incorporated on 19 July 1991 with the following objectives:

to relieve those suffering the effects of heart disease and in particular lipid disorders, familial hyperlipidaemias and related conditions;

to promote the relief of sickness and the preservation and protection of health by reducing the incidence of vascular disease in the general population of the United Kingdom;

to provide counselling and advice to relatives of those diagnosed with inherited heart disease; and

to promote the study of causes, diagnosis and treatment of lipid disorders and associated metabolic diseases.

The Company also has a trading subsidiary whose principal activities are currently the sale of publications and other material in relation to heart disease and the approval of beneficial health products.

RESULTS

The Charity had consolidated outgoing resources of £27,310 (2004: £45,475) after meeting its expenditure.

The Charity's own activities, excluding subsidiaries, resulted in net outgoing resources of £32,874.

REVIEW OF GROUP FINANCIAL POSITION

	2005	2004
	£	as restated £
Income for the year	600,005	598,304
Expenditure for the year	627,315	643,779
Total funds carried forward	<u>100,923</u>	<u>128,032</u>

HYPERLIPIDAEMIA EDUCATION AND RESEARCH TRUST UK

(A Company Limited by Guarantee)

DIRECTORS' REPORT

DEVELOPMENTS, ACTIVITIES AND ACHIEVEMENTS THIS YEAR

The Mission Statement

Hyperlipidaemia Education and Research Trust UK (H·E·A·R·T UK) works to break the deadly round of preventable heart attacks and strokes affecting young families with inherited high cholesterol (IHC) by raising the broadest awareness of this silent disease and to work in order to provide effective and economic health solutions.

Introduction

H·E·A·R·T UK is primarily concerned with the prevention and risk management of cardiovascular diseases and specifically with attention to inherited high cholesterol (IHC).

Inherited High Cholesterol

The two main arms of IHC are Familial Hypercholesterolaemia (FH) and Familial Combined Hyperlipidaemia (FCH). Both result in the serious increased risk of premature cardiovascular disease. The average age of a first infarction (heart attack/stroke) in men with FH, is 45 years, but an event may well, and often does, occur much earlier in life, sometimes as young as the early twenties. One in three of these people do not survive their first infarction (heart attack/stroke). Infarction nearly always has a negative effect on patients' future career prospects and their families' social and mental wellbeings. FH is a dominant disease, meaning that there is always a fifty percent chance of the disorder being passed on to the next generation. However once diagnosed, IHC is very well treated, and can in most cases result in the prevention of further disease and risk onset. And for many, the benefits of early prevention may result in decades of longer life.

...400,000 patients, with dangerously high levels of cholesterol...

In 2005, about 120,000 men, women and children in the UK have FH and maybe up to half a million have FCH. It should be most importantly noted, that it is estimated that only about a fifth of the former figure patients have been diagnosed, and although presently very little is known about diagnosed FCH patients, it may be well less than 10%. Simply extrapolated, that means in the UK over 400,000 patients, with dangerously high levels of cholesterol, remain today, undiagnosed.

..devoted to prevention, risk management and advocacy..

H·E·A·R·T UK aims to help families with a high risk of premature inherited cardiovascular disease, especially inherited high cholesterol. It wants to break the vicious cycle of unnecessary heart attacks and death in young people from families with an inherited high risk, and to ensure that people can stay healthy rather than become ill. People with an inherited high risk must be able to make informed choices and be able to manage their own health, so H·E·A·R·T UK wants to encourage innovative approaches to prevention by sharing scientific information, knowledge and expertise from the broad-based international network in which it takes part with those concerned. It wants to offer a platform for exchanging information about healthy living and state-of-the-art treatment of high-risk patients, and works hard to ensure that all individuals affected by these conditions are able to receive the medical treatment they need, which may save lives.

HYPERLIPIDAEMIA EDUCATION AND RESEARCH TRUST UK

(A Company Limited by Guarantee)

DIRECTORS' REPORT

To this end it works together with all parties that can contribute to helping it achieve its goal. As diseases often occur in combination (for example, cardiovascular disease, stroke and dementia), timely and good prevention in high-risk groups is extremely important in the long term. People who are interested in their own health and well-being seem to play a more active role in managing their risk and/or condition. This is reflected in, for example, efficient handling of medical needs, better health outcomes and improved therapy compliance.

...one in two chance of suddenly contracting cardiovascular disease before the age of 50.

The damage caused is initially almost imperceptible to those affected, but drugs can be very useful in a prophylactic role, effectively countering the consequences of a significantly increased risk. Men with familial hypercholesterolemia (FH) who do not receive preventive treatment have more than a one in two chance of suddenly contracting cardiovascular disease before the age of 50. Women in the same position have a 30% chance of a heart attack before the age of 60. One in three will not survive their first heart attack. Fortunately effective evidence-based medical treatment for this high-risk group is widely accepted throughout the world.

...more than three quarters of IHC people remain undiagnosed...

Despite the evidence showing high risk of early death, more than three quarters of IHC people remain undiagnosed and untreated. Where they are diagnosed, there remains an enormous gap between those who should be treated according to medical guidelines and those who actually receive that treatment. All IHC patients meet present day medical guidelines for treatment. Self-recognition of IHC is neither simple nor obvious, it is thus a dangerously silent disease - giving rise to lives that are quite normally led until the very moment of a first heart attack or stroke.

H·E·A·R·T UK provides free information, advice and help to all those concerned, and intends to bring forward for those who will benefit most, a programme of healthy lifestyle change combined with preventive medical treatment that in partnership helps prevent premature cardiovascular disease.

H·E·A·R·T UK encourages IHC people to gain better risk knowledge leading to greater skills that will inevitably help patients and their families to better manage their own health.

H·E·A·R·T UK endeavours to achieve well balanced, meaningful and more equal relationships between doctors, health providers and IHC patients.

H·E·A·R·T UK seeks to improve the quality of treatment by encouraging medical professionals to adhere to existing and upcoming clinical guidelines and treatment goals.

H·E·A·R·T UK seeks to attain these goals through flexible individual adapted pharmacotherapy and lifestyle choices.

H·E·A·R·T UK seeks, with IHC patient participation, to actively promote strong political programmes aimed at timely prevention strategies of treatable high risks.

H·E·A·R·T UK continues to encourage research into disease control and long term health improvement, through patient self-management.

HYPERLIPIDAEMIA EDUCATION AND RESEARCH TRUST UK

(A Company Limited by Guarantee)

DIRECTORS' REPORT

H·E·A·R·T UK seeks to promote fair and equal access to medical treatments – medical treatments that are set as guideline gold standards. Provision and reimbursement of affordable medicines are of the utmost importance in order to achieve effective preventive treatment of inherited high cholesterol.

H·E·A·R·T UK represents and lobbies on behalf of those who stand to benefit from preventive treatment in order to ensure they receive what is rightfully theirs.

H·E·A·R·T UK educates on the basis of principles that rely on evidence based medicine solutions, best practices and solid and experienced knowledge gained through its UK, European and global networks.

H·E·A·R·T UK continues to see, for the eighth year in succession, a rise in demand for its services, in all core activities: communications and education (targeted mainly at prevention), advocacy and the mutual exchange of information between people with inherited high cholesterol, in partnership with health care professionals, the Government and commercial partners.

H·E·A·R·T UK's helpdesk received 25% more telephone enquiries in the financial year compared to the previous year 2003/2004, and overall, the Charity advisers were contacted 2,500 times, an average of ten calls each working day of the year. The number of information packs sent out to individuals also increased in line with enquiries, and there was a significant increase in the number of information packs sent out to government, media, trusts and commercial organisations in the financial year ending 2005.

The Digest Magazine

The Digest is edited and made ready for print entirely in house, by staff of H·E·A·R·T UK. It is produced bi-monthly and distributed to up to 20,000 readers, who are member patients and health care professionals, as well as readers in lipid, cardio, other hospital clinics and those from the commercial, media, and government fields. This publication is highly regarded in all fields of readership and is submitted to by freelance lay and physician journalists from around the world. Major articles are always submitted for inclusion and search upon the Charity's website. Through the standing of the Digest two surveys, one patient/member and one health professional are planned for the forthcoming financial year.

Government Funding – Helpdesk Nurse Counsellor

Core 64 funding was made available for a period of three years with this financial year 2004/5 being the first in sequence. £30,000 was made available to fund one additional member of staff as a Helpdesk Nurse Counsellor, who has provided much needed additional resource to meet the increase in demand for patient support and knowledge both in medical terms as well as nutrition information needs.

Calls are taken from members, including patients and health care professionals and members of the public. Access to the H·E·A·R·T UK contact details come from varied sources including the patient information leaflet inserted in the drug packet of many lipid lowering drugs. Other charities and organisations also contribute including the British Heart Foundation, Blood Pressure Association and NHS Direct. Media awareness campaigns and news features also provide contact details for patients to contact H·E·A·R·T UK. New drugs and drug formats, such as over the counter statins as well as foods recommended as part of healthy diets, running alongside raised Charity profile, have accounted for a wider and greater need for understandings by both patient and practitioner.

HYPERLIPIDAEMIA EDUCATION AND RESEARCH TRUST UK

(A Company Limited by Guarantee)

DIRECTORS' REPORT

Government Funding – Children's Lipid Clinics

Core 64 funding was made available for a period of three years with this financial year 2004/5 being the first in sequence. £30,000 was made available to carry forward the project and open a new additional centre in Birmingham. This project (already piloted in London and Cardiff) focuses on children and their families with familial hypercholesterolemia who are at high risk of premature death from coronary heart disease.

The programme runs over 4 months, incorporating four sessions focusing on health and health promotions specific to their condition. After each educational session the children and their parents undergo supervised fitness assessment and training.

This project aims to educate the children and their parents about their genetic disorder and what they can do to help themselves in the way of lifestyle changes and medication.

Provisional data from the London and Cardiff Children's Lipid Clinics show that many of the children treated for FH have no idea about their condition, the management of their condition, treatment or the medication and how that medication works. Those who have already gone through the programme improved their fitness level by 55% thereby improving their cardiovascular fitness and potentially delaying development of coronary heart disease.

Family Support Centres

Small start up funding of £5,359 has been allocated to the setting up of the first Family Support Centre in Birmingham. It is expected that this will be on line towards the end of 2005. It will align itself with the Children's Lipid Clinic and one of five Government funded Cascade Centres to support local patients and their families. Regular presentations and meetings will take place and health professionals will be integral to the project offering on-hand support and advice. H·E·A·R·T UK expects to launch a further centre in Newcastle toward the end of 2006.

Genetic Knowledge Parks (GKP).

H·E·A·R·T UK continues to be a partner of the London IDEAS Genetics Knowledge Park. Highlights that have direct connection to H·E·A·R·T UK's overall role include the setting up of five sites to participate in the FH National Cascade Testing Project.

National Cascade Testing Project.

The Familial Hypercholesterolemia Cascade Testing Pilot Project, funded by the Department of Health now has five centres on line in England in Birmingham, Manchester, Guildford, Nottingham and Bournemouth. H·E·A·R·T UK has been asked to recommend a logistics roll out programme to be considered on completion of pilot studies.

NICE (National Institute for Clinical Excellence).

The National Institute for Clinical Excellence works on behalf of the National Health Service and the people who use it, and makes recommendations on treatments and care using the best available evidence. During the year H·E·A·R·T UK has been called on to make a number of appraisals on behalf of the 'patient', and physician, including the major issue of statins.

HYPERLIPIDAEMIA EDUCATION AND RESEARCH TRUST UK

(A Company Limited by Guarantee)

DIRECTORS' REPORT

H·E·A·R·T UK Website

The website www.heartuk.org.uk recorded over two million hits and was visited by over 65,000 people in the period, specifically requesting information from H·E·A·R·T UK by name address, resulting in therefore about 300 unique hits a day. A newly formatted website will be launched toward the end of 2005 – one that provides greater access support for children, greater pro-active communication with physicians and their staff, particularly those in lipid clinics and better information about support centres in the UK.

Conferences

H·E·A·R·T UK holds one major scientific and research two day conference each year, a health care conference and two patient conferences. Staff, trustee Directors and committee members attend and present at major science conferences in the UK and abroad.

Associations

H·E·A·R·T UK is a member of the following Alliances and Associations:

1. National Heart Forum (www.heartforum.org.uk)
2. Cholesterol UK (www.cholesterol.co.uk) an initiative of two leading heart charities H·E·A·R·T UK and the British Cardiac Patients' Association.
3. HEART EU - the European Cholesterol Patient Foundation & Hyperlipidaemia Education Action Research Treatment was set up in the year under review with partner organisation in the United Kingdom, The Netherlands and Spain. The two main objectives of HEART EU are to offer information at European level and to work for the establishment of similar patient organisations in other EU countries.

H·E·A·R·T UK also works closely and enthusiastically in partnership with other international health professionals including MEDPED (a global not-for-profit organisation linking international clinicians who are seeking better diagnosis and treatment of IHC patients – www.medped.org as well as IAPO (the International Association of Patient Organisations), EAS (the European Atherosclerosis Society), GIG (Genetics Interest Group), European Public Health Alliance (EPHA) and the European Children's Network (EURONET).

Financing and Funding

Without financial support, including donations, gifts, legacies, subsidies and sponsorship from persons, companies, trust funds, and government, H·E·A·R·T UK would not be able to realise its programmes. Where there are no conflicting interests, H·E·A·R·T UK accepts non-restrictive financial and pro bono support from pharmaceutical and food companies and other corporate body organisations. To ensure the long term existence and quality of the organisation, H·E·A·R·T UK seeks to achieve consistent continuity of income, which is well balanced between industry, enterprise, government and others. H·E·A·R·T UK's Board of Trustee Directors provide their services without charge.

It is the intention of that Board to continue to seek ways in which it may increase the Charity's own reserves to 1.5 times the operating costs, in line with best practice recommendations.

HYPERLIPIDAEMIA EDUCATION AND RESEARCH TRUST UK

(A Company Limited by Guarantee)

DIRECTORS' REPORT

In order to achieve its aims, H·E·A·R·T UK will continue to seek to work with all key stakeholders, be they commercial, government or private, who are able in no particular order of priority or favour, to contribute from healthcare, Charity or corporate sectors, with the fullest positive support.

Summary of the Year 2004/2005

The consistent growth in demand for the services provided by H·E·A·R·T UK seen in previous years was maintained in the financial year 2004/05. This increase was seen in all core activities. The following issues formed the core of H·E·A·R·T UK's activities in 2004/5

1. Raising awareness of a significantly elevated risk of premature illness and death as effective treatment, including a healthy lifestyle, becomes more available
2. General education about all aspects of inherited high cholesterol and prevention strategies which have proven effective in scientific research and practice
3. Improving access to the necessary preventive care for people at significantly greater risk, who are entitled to such access in accordance with medical guidelines
4. Better quality standards of everyday treatment in accordance with treatment aims formulated in medical guidelines, with more opportunity for tailor-made treatment
5. Broadening and deepening understanding of risk reduction in people with inherited high cholesterol so that they can take more responsibility for their own health, including treatment compliance
6. Expanding knowledge networks and intensifying cooperation with the key stakeholders so that the objectives H·E·A·R·T UK can be attained sooner and more comprehensively

H·E·A·R·T UK is working with a number of patient organisations to develop a code of conduct for cooperation with business.

FUTURE STRATEGY

The Board looks to a continued increase in cross line partnership that not only includes such major commercial players as mentioned, but new and more diversified partners. The Charity expects to see more emphasis upon patient membership recruitment and thus a greater patient voice in the public arena. Proactive, multi faceted relationships and partnerships with government, health services and charities, commerce and trust fund holders, are keys to the future of H·E·A·R·T UK.

ORGANISATION

H·E·A·R·T UK is constituted as a company limited by guarantee, and is therefore governed by a memorandum and articles of association. The Board oversees the running of the Charity and meets regularly to manage the affairs.

The Charity is an organisation that is manned by part and full-time employees, engaged in health counselling, fund-raising, office and membership administration.

HYPERLIPIDAEMIA EDUCATION AND RESEARCH TRUST UK

(A Company Limited by Guarantee)

DIRECTORS' REPORT

The Board is structured to comprise presently of 12 Directors, who are selected for their health professional, financial and patient expertise, experience and skills. The Directors, supported by sub committees, notably Finance and General Purpose, Medical Scientific & Research, Healthcare Section and Patient Services, meet formally on a regular basis at least four times a year. The Finance and General Purpose Committee meets to establish budgets and to monitor the Charity's financial position, reviewing existing strategy and potential business and dealing with, for instance, personnel matters.

FINAL THANKS

H·E·A·R·T UK wishes to record its thanks to all those who have supported and continue to do so, in whatever way that is manifested but notably in helping with early diagnosis that can help prevent early death, in patient and family counselling and support as well as in funding and research.

Finally, H·E·A·R·T UK would like to thank all its donors, sponsors, backers and volunteers, without whose support its organisation's work would be impossible.

RISK MANAGEMENT

Risk management is recognised as an important issue and addressed in the Charity Handbook, distributed and promoted to all employees. Sections within this publication address key topics including health & safety, risk assessment, code of practice, complaints and abuse directives. The employees handbook will be renewed annually.

It is intended that risk management will appear as a major Board agenda item at least once a year for review and upgrading where necessary.

The Board has adopted a policy of risk management, covering both commercial and financial aspects of the Charity. This policy will be regularly reviewed and updated when appropriate, by the Board.

RESERVES POLICY

The Charity has both restricted and unrestricted income resources. Restricted funding relates to various projects that may be of indeterminate duration and may for instance include such work in the health sector as family screening and children's health

Unrestricted income including membership fees, sponsorship, product recommendation and donations are primarily intended for education, research, literature, conferences and fund-raising costs. Administrative costs are also financed from this resource.

All main funding resources are considered subject to risk as projects can often be suspended or terminated with only limited notice.

The Charity is believed to have exposure to these risks and thus recognises the need to protect its own, employees' and members' positions from any erosion in the Charity's asset base. For this reason the Board is working towards accumulating over a number of years, a Reserve fund equivalent to between six and nine months based on regular expenditure. This position will be reviewed regularly, in the light of the Charity's circumstances and the level of its income security.

HYPERLIPIDAEMIA EDUCATION AND RESEARCH TRUST UK

(A Company Limited by Guarantee)

DIRECTORS' REPORT

EMPLOYMENT STRATEGY

The Charity is committed to equal opportunities and encourages recruitment and employment of the best candidate for appointment, regardless of gender, marital status, ethnic origins, disability, religion or age.

CHARITY PERSONNEL

The work of the Charity is made possible solely through the endeavours and dedication provided by its full and part time staff, volunteers and through pro bono services. The Directors wish to place on record their gratitude for the efforts given.

SUBSIDIARY COMPANY

H·E·A·R·T UK has an established active trading Company – HEART UK Trading Company Limited – that currently trades in publications and exploits the potential of ongoing long-term approvals of beneficial health products, notably foods. The profits of the trading Company are gifted to the Charity.

DIRECTORS

The Directors who served during the year were as follows:

Dr J P D Reckless	
Mrs D Davies	(Appointed 2 December 2004)
Mrs Y Dumsday	
Mr R B Edwards FCA	
Dr E A Hughes	
Mr E A Lazarus	
Dr M I Mackness	(Resigned 1 July 2004)
Dr J M Morrell	(Resigned 1 July 2004)
Professor A Neil	(Appointed 2 December 2004)
Dr R D G Neely	
Professor N Sattar	
Dr F C Sivers	
Mr A R Smith	(Resigned 1 July 2004)
Dr A S Wierzbicki	
Dr J W Wright	

The following Directors stand for re-election by rotation at the forthcoming Annual General Meeting:

Mr R B Edwards FCA
Dr J P D Reckless
Dr A S Wierzbicki
Dr J W Wright

The Company has taken out insurance cover to indemnify officers and Directors against any personal liability arising from their involvement with the Company's activities.

HYPERLIPIDAEMIA EDUCATION AND RESEARCH TRUST UK

(A Company Limited by Guarantee)

DIRECTORS' REPORT

DIRECTORS' RESPONSIBILITIES IN RELATION TO THE FINANCIAL STATEMENTS

Company law requires the Directors to prepare financial statements that give a true and fair view of the state of affairs of the Charity at the end of the financial year and of its surplus or deficit for the financial year. In doing so the trustees are required to

- select suitable accounting policies and then apply them consistently;
- make judgements and estimates that are reasonable and prudent; and
- prepare the financial statements on the going concern basis unless it is inappropriate to presume that the Charity will continue in business.

The Directors are responsible for maintaining proper accounting records which disclose with reasonable accuracy at any time the financial position of the Charity and enables them to ensure that the financial statements comply with the Companies Act 1985.

TANGIBLE FIXED ASSETS

Details of movements in fixed assets are found in notes 8 & 9 to the accounts.

AUDITORS

The auditors, Rothman Pantall & Co, have expressed their willingness to continue in office. A resolution proposing their reappointment and authorising the Directors to fix remuneration will be proposed at the Annual General Meeting.

SMALL COMPANY EXEMPTION

The above report has been prepared in accordance with the special provisions of Part VII of the Companies Act 1985 relating to small companies.

**Signed on behalf of the
Board of Directors**

Michael Livingston

**Mr M Livingston
Secretary**

Dated: 29 June 2005

**INDEPENDENT AUDITORS' REPORT TO THE MEMBERS OF
HYPERLIPIDAEMIA EDUCATION AND RESEARCH TRUST UK
YEAR ENDED 30 APRIL 2005**

We have audited the financial statements on pages 13 to 24 which have been prepared under the historical cost convention and the accounting policies set out on pages 17 & 18.

This report is made solely to the charity's members, as a body, in accordance with Section 235 of the Companies Act 1985. Our audit work has been undertaken so that we might state to the charity's members those matters which we are required to state to them in an auditors' report and for no other purpose. To the fullest extent permitted by law, we do not accept or assume responsibility to anyone other than the charity and the charity's members, for our audit work, for this report, or for the opinions we have formed.

Respective responsibilities of directors and auditors

As described on page 11 the trustees are responsible for the preparation of the directors' report and the financial statements. It is our responsibility to form an independent opinion, based on our audit, on those financial statements and to report our opinion to you. We also report to you if, in our opinion, the directors' report is not consistent with the financial statements.

Basis of opinion

We conducted our audit in accordance with Auditing Standards issued by the Auditing Practices Board. An audit includes examination, on a test basis, of evidence relevant to the amounts and disclosures in the financial statements. It also includes an assessment of the significant estimates and judgements made by the directors in the preparation of the financial statements, and of whether the accounting policies are appropriate to the circumstances of the charity, consistently applied and adequately disclosed.

We planned and performed our audit so as to obtain all the information and explanations which we considered necessary in order to provide us with sufficient evidence to give reasonable assurance that the financial statements are free from material misstatement, whether caused by fraud or other irregularity or error. In forming our opinion we also evaluated the overall adequacy of the presentation of information in

Opinion

In our opinion the financial statements give a true and fair view of the state of the group's and charity's affairs as at 30 April 2005 and of the group's incoming resources and application of resources, including the group's income and expenditure, in the year then ended and have been properly prepared in accordance with the Companies Act 1985.

Rothman Pantall & Co
5 July 2005

ROTHMAN PANTALL & CO
*Chartered Accountants
and Registered Auditors*

HYPERLIPIDAEMIA EDUCATION AND RESEARCH TRUST UK

(A Company Limited by Guarantee)

CONSOLIDATED STATEMENT OF FINANCIAL ACTIVITIES (Including Income and Expenditure Account)

FOR THE YEAR ENDED 30 APRIL 2005

	Note	Unrestricted Funds	Restricted Funds	Total	2004 as restated
		£	£	£	£
Donations, legacies and similar incoming resources:					
Corporate donations		58,413	276,695	335,108	331,455
Other donations		27,634	0	27,634	24,538
Transfer following merger		0	0	0	22,658
Activities in furtherance of charities objectives:					
Publication and literature		73,109	0	73,109	57,078
Membership fees		33,698	0	33,698	24,979
Sponsorship		65,313	0	65,313	84,733
Activities to generate funds:					
Product recommendations		60,989	0	60,989	50,500
Investment income:					
Interest received		4,093	0	4,093	2,356
Dividend income		61	0	61	7
TOTAL INCOMING RESOURCES		323,310	276,695	600,005	598,304
RESOURCES EXPENDED					
Costs of generating funds					
Publicity and fundraising	4	71,968	0	71,968	45,505
Administrative expenses	5	132,414	0	132,414	90,578
Charitable expenditure	6	151,802	271,131	422,933	507,696
TOTAL RESOURCES EXPENDED		356,184	271,131	627,315	643,779
NET INCOME/(EXPENDITURE) FOR THE YEAR		(£32,874)	£5,564	(£27,310)	(£45,475)
Gain/(Loss) on investment unrealised		201	0	201	(3)
NET MOVEMENT IN FUNDS		(32,673)	5,564	(27,109)	(45,478)
Fund balance at 1 May 2004		81,460	46,572	128,032	173,509
Fund balance at 30 April 2005		48,787	£52,136	£100,923	£128,032

HYPERLIPIDAEMIA EDUCATION AND RESEARCH TRUST UK

(A Company Limited by Guarantee)

STATEMENT OF TOTAL RECOGNISED GAINS AND LOSSES

FOR THE YEAR ENDED 30 APRIL 2005

	Unrestricted Funds	Restricted Funds	Total	2004 as restated
	£	£	£	£
NET MOVEMENT IN FUNDS	(32,673)	5,564	(27,109)	(45,478)
TOTAL RECOGNISED GAINS AND LOSSES RELATING TO THE YEAR	<u>(32,673)</u>	<u>5,564</u>	<u>(27,109)</u>	<u>(45,478)</u>
PRIOR YEAR ADJUSTMENT	(22,683)	0	(22,683)	
TOTAL GAINS AND LOSSES RECOGNISED SINCE LAST ANNUAL REPORT	<u><u>(55,356)</u></u>	<u><u>5,564</u></u>	<u><u>(49,792)</u></u>	

HYPERLIPIDAEMIA EDUCATION AND RESEARCH TRUST UK

(A Company Limited by Guarantee)

CONSOLIDATED BALANCE SHEET FOR THE YEAR ENDED 30 APRIL 2005

		2005		2004 as restated	
	Note	£	£	£	£
FIXED ASSETS					
Tangible fixed assets	9		5,613		5,281
Investments	11		643		442
			<u>6,256</u>		<u>5,723</u>
CURRENT ASSETS					
Debtors	12	234,654		166,196	
Cash at bank and in hand		73,776		142,968	
		<u>308,430</u>		<u>309,164</u>	
CREDITORS: amounts falling due within one year					
	13	213,763		186,855	
		<u>213,763</u>		<u>186,855</u>	
NET CURRENT ASSETS					
			<u>94,667</u>		<u>122,309</u>
TOTAL ASSETS LESS CURRENT LIABILITIES					
			<u>100,923</u>		<u>128,032</u>
NET ASSETS					
			<u><u>£100,923</u></u>		<u><u>£128,032</u></u>
REPRESENTED BY					
Restricted funds	14		52,136		46,572
Unrestricted funds	15		44,445		77,280
Non-charitable trading funds held by subsidiaries	15		4,342		4,180
			<u>100,923</u>		<u>128,032</u>
			<u><u>£100,923</u></u>		<u><u>£128,032</u></u>

The financial statements on pages 13 to 24 were approved by the board of directors on 29 June 2005.

John Reckless

Ray Edwards

Dr J P D Reckless
Director

Mr R B Edwards FCA
Director

HYPERLIPIDAEMIA EDUCATION AND RESEARCH TRUST UK

(A Company Limited by Guarantee)

BALANCE SHEET

FOR THE YEAR ENDED 30 APRIL 2005

		2005		2004 as restated	
	Note	£	£	£	£
FIXED ASSETS					
Tangible fixed assets	10		2,394		2,461
Investments	11		645		443
			<u>3,039</u>		<u>2,904</u>
CURRENT ASSETS					
Debtors	12	236,365		169,464	
Cash at bank and in hand		63,889		120,405	
		<u>300,254</u>		<u>289,869</u>	
CREDITORS: amounts falling due within one year	13	206,712		168,921	
		<u></u>		<u></u>	
NET CURRENT ASSETS			<u>93,542</u>		<u>120,948</u>
TOTAL ASSETS LESS CURRENT LIABILITIES			<u>96,581</u>		<u>123,852</u>
NET ASSETS			<u>£96,581</u>		<u>£123,852</u>
REPRESENTED BY					
Restricted Funds	14		52,136		46,572
Unrestricted Funds	15		44,445		77,280
			<u>£96,581</u>		<u>£123,852</u>

The financial statements on pages 13 to 24 were approved by the board of directors on 29 June 2005.

John Reckless

Ray Edwards

Dr J P D Reckless
Director

Mr R B Edwards FCA
Director

HYPERLIPIDAEMIA EDUCATION AND RESEARCH TRUST UK

(A Company Limited by Guarantee)

NOTES TO THE FINANCIAL STATEMENTS

FOR THE YEAR ENDED 30 APRIL 2005

1. ACCOUNTING POLICIES

The accounts have been prepared under the historical cost convention and in accordance with the Statement of Recommended Practice, Accounting and Reporting by Charities (SORP 2000) issued in October 2000, the Financial Reporting Standard for Smaller Entities (effective June 2002) and the Companies Act 1985. These financial statements consolidate the results of the charity and its wholly owned subsidiary Heart UK Trading Company Limited on a line by line basis. A separate Statement of Financial Activities has not been presented because the Charity has taken advantage of the exemptions afforded by the Companies Act 1985 and SORP 2000. The principal accounting policies adopted in the preparation of the financial statements are as follows:

(i) Donations and grants

Income from donations and sponsorship is included in incoming resources when these are receivable, except when donors specify that donations and sponsorship must be used in future accounting periods.

(ii) Resources expended

Resources expended are included in the Statement of Financial Activities on an accruals basis, inclusive of any VAT which cannot be recovered.

Certain expenditure is directly attributable to specific activities and has been included in those cost categories. Certain other costs, which are attributable to more than one activity, are apportioned across other categories on the basis of an estimate of the proportion of time spent by staff on those activities.

(iii) Legal status of the charity

The charity is a company limited by guarantee and has no share capital. The liability of each member is limited to £1, which is payable in the event of the company being wound up.

(iv) Fixed Assets

Depreciation is provided at the following annual rates in order to write off each asset over its estimated useful life :

Plant and equipment 8.5% - 25% reducing balance

All tangible fixed assets are initially recorded at cost, and listed investments are included at market value at the year end.

(v) Operating Leases

The rentals payable under operating leases are charged in the Statement of Financial Activities as incurred over the lease term.

HYPERLIPIDAEMIA EDUCATION AND RESEARCH TRUST UK

(A Company Limited by Guarantee)

NOTES TO THE FINANCIAL STATEMENTS

FOR THE YEAR ENDED 30 APRIL 2005

1. ACCOUNTING POLICIES (CONTINUED)

(vi) Pensions

The company operates a Stakeholder (defined contribution) pension scheme. Contributions are charged to the profit and loss account as they become payable in accordance with the rules of the scheme.

(vii) Donated Goods

Donations includes the estimated market value of gifts of tangible fixed assets which have been capitalised.

(viii) Basis of Consolidation

The consolidated financial statements include the charity and its subsidiary, Family Heart Trading Co. Limited. Intra-group sales and income are eliminated on consolidation and all sales and income figures relate to external transactions only. Income from the subsidiary and its balance sheet are incorporated on a 'line by line' basis.

(ix) Restricted, Designated and Unrestricted Funds

Restricted funds are funds subject to specific conditions imposed by the donor which are binding on the trustees.

Designated funds are a form of unrestricted fund, which has been allocated or designated for specific purposes by the charity itself. The use of designated funds for their designated purpose will remain at the discretion of the trustees.

Unrestricted funds have no restrictions on their use.

2. OPERATING SURPLUS/DEFICIT - GROUP

	2005	2004
	£	as restated £
The operating surplus/deficit is stated after charging:		
Depreciation of tangible fixed assets	1,097	1,082
Hire of equipment	5,206	3,712
Auditors' remuneration	4,250	2,750
Employee pension	8,853	8,841

HYPERLIPIDAEMIA EDUCATION AND RESEARCH TRUST UK

(A Company Limited by Guarantee)

NOTES TO THE FINANCIAL STATEMENTS

FOR THE YEAR ENDED 30 APRIL 2005

3. NET INCOME FROM TRADING ACTIVITIES OF SUBSIDIARIES

The wholly owned trading subsidiary, Heart UK Trading Company Limited, which is incorporated in the United Kingdom, pays its taxable profits to the charity by Gift Aid. Its results are consolidated with those of H·E·A·R·T UK. Its objects are to raise money for the charity and donate the proceeds as gift aid. The charity owns the entire share capital of 2 ordinary shares of £1. A summary of the trading results is shown below.

	2005	2004
	£	as restated £
Turnover	111,112	60,636
Cost of sales and administrative expenses	(43,333)	(39,960)
Interest receivable	575	323
	<hr/>	<hr/>
Net profit	68,354	20,999
Amount gifted to the charity	(68,192)	(19,601)
	<hr/>	<hr/>
Retained in the subsidiary	162	1,398
	<hr/> <hr/>	<hr/> <hr/>
The assets and liabilities of the subsidiary were:		
Fixed and current assets	68,638	89,941
Creditors: amounts falling due within one year	(64,294)	(85,759)
	<hr/>	<hr/>
Total net assets	4,344	4,182
	<hr/> <hr/>	<hr/> <hr/>
Aggregate share capital and reserves	4,344	4,182
	<hr/> <hr/>	<hr/> <hr/>

4. COSTS OF GENERATING FUNDS

	2005	2004
	£	as restated £
Fundraising and publicity	16,610	17,512
Fundraising salaries	45,425	17,269
Travel, postage and stationery	8,366	7,930
Membership expenses	1,567	2,794
	<hr/>	<hr/>
	£71,968	£45,505
	<hr/> <hr/>	<hr/> <hr/>

HYPERLIPIDAEMIA EDUCATION AND RESEARCH TRUST UK

(A Company Limited by Guarantee)

NOTES TO THE FINANCIAL STATEMENTS

FOR THE YEAR ENDED 30 APRIL 2005

5. ADMINISTRATIVE EXPENSES	2005	2004
		as restated
	£	£
Salaries and wages	58,771	28,574
Staff pension costs	8,853	8,841
Office expenses	465	3,103
Computer expenses	81	1,125
Telephone, postage and stationery	14,873	14,417
Insurance	732	(527)
Legal and professional fees	490	2,166
Audit and accountancy fees	19,763	13,717
Bookkeeping fees	4,676	436
Bank charges	1,835	1,021
Sundry expenses and cleaning	730	975
Subscriptions	1,377	0
Hire of equipment	5,206	3,712
Depreciation	1,097	1,082
Rent and services	13,465	11,936
	£132,414	£90,578

6. CHARITABLE EXPENDITURE	2005	2004
		as restated
	£	£
Information services	76,511	63,892
Information services salaries	10,135	41,253
Conference costs	44,418	92,810
Website costs	8,823	7,077
Simon Broome	24,357	29,401
Lipid Clinics	17,003	59,119
Lipid Clinic salaries	4,907	0
Cascade testing	11,915	0
Helpline costs	1,570	34,827
Helpline salaries	29,192	0
Laboratory committee	474	0
Cholesterol UK	193,628	179,317
	£422,933	£507,696

HYPERLIPIDAEMIA EDUCATION AND RESEARCH TRUST UK

(A Company Limited by Guarantee)

NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 30 APRIL 2005

7. STAFF COSTS AND TRUSTEES' REMUNERATION	2005	2004
	£	as restated £
Wages and salaries	148,430	121,923
Pension costs	8,853	8,841
	157,283	130,764

The wages and salaries have been allocated on a different basis to previous years in order to better reflect how staff time is split between the different activities of the charity.

No employee earned more than £50,000 per annum (2004 - nil).

The directors did not receive any emoluments for their services as directors or trustees in the current or preceding year, and were reimbursed for £1,019 (2004 - £693) worth of expenses during the year.

Indemnity insurance, costing £798 (2004: -527) was purchased by the charity to indemnify officers and Directors' against any personal liability arising from their involvement with the Company's activities.

The average number of full-time equivalent employees (including casual and part time staff) during the year was made up as follows:

	2005	2004
Average number of employees	7	7

8. PRIOR YEAR ADJUSTMENT

These accounts have been amended so that the annual conference is accounted for on an accruals basis, whereas in the past it has been accounted for on a receipts basis. The effect of the prior year adjustment is to increase the closing reserves as at 30 April 2005 by £20,394.

9. TANGIBLE FIXED ASSETS - GROUP

	Plant & Machinery £
Cost	
As at 1 May 2004	11,909
Additions	1,429
As at 30 April 2005	13,338
Depreciation	
As at 1 May 2004	6,628
Charge for the year	1,097
As at 30 April 2005	7,725
Net book value	
As at 30 April 2005	5,613
As at 30 April 2004	5,281

HYPERLIPIDAEMIA EDUCATION AND RESEARCH TRUST UK

(A Company Limited by Guarantee)

NOTES TO THE FINANCIAL STATEMENTS

FOR THE YEAR ENDED 30 APRIL 2005

10. TANGIBLE FIXED ASSETS - CHARITY

	Plant & Machinery £
Cost	
As at 1 May 2004	7,018
Additions	731
As at 30 April 2005	<u>7,749</u>
Depreciation	
As at 1 May 2004	4,557
Charge for the year	798
As at 30 April 2005	<u>5,355</u>
Net book value	
As at 30 April 2005	<u>2,394</u>
As at 30 April 2004	<u>2,461</u>

11. INVESTMENTS

	Other Investments £	
Cost		
As at 1 May 2004		442
Revaluation		201
As at 30 April 2005		<u>643</u>
Other investments	2005	2004 as restated
	£	£
Listed investments	643	442
	<u>643</u>	<u>442</u>
Listed investments at market value	643	442
	<u>643</u>	<u>442</u>

Investments held by the charity also include an additional £2 (2004 - £2) investment in the subsidiary company at cost.

HYPERLIPIDAEMIA EDUCATION AND RESEARCH TRUST UK

(A Company Limited by Guarantee)

NOTES TO THE FINANCIAL STATEMENTS

FOR THE YEAR ENDED 30 APRIL 2005

12. DEBTORS

	Group 2005	Charity 2005	Group 2004 as restated	Charity 2004 as restated
	£	£	£	£
Trade debtors	33,290	29,078	63,645	11,914
Prepayments and accrued income	201,364	150,044	102,479	89,653
Amounts due from associated undertakings	0	57,243	0	67,825
Other debtors	0	0	72	72
	£234,654	£236,365	£166,196	£169,464

13. CREDITORS: amounts falling due within one year

	Group 2005	Charity 2005	Group 2004 as restated	Charity 2004 as restated
	£	£	£	£
Trade creditors	106,094	105,225	90,291	89,909
Other taxes and social security costs	8,119	4,724	10,345	4,293
Life members funds	6,628	6,628	4,964	4,964
Sundry creditors and accruals	92,922	90,135	81,255	69,755
	£213,763	£206,712	£186,855	£168,921

14. RESTRICTED INCOME FUNDS

	Balance 2004 as restated	Incoming Resources	Expenditure and transfers	Balance 2005
	£	£	£	£
Audrey Brent Memorial fund	3,932	0	0	3,932
Simon Broome fund	18,200	12,000	(24,357)	5,843
Cholesterol UK	0	193,628	(193,628)	0
Lipid clinic fund	4,267	30,000	(21,910)	12,357
Helpline funding	173	32,708	(30,762)	2,119
Pre -registrar training	10,000	0	0	10,000
Cholesterol disease awareness campaign	10,000	0	0	10,000
Birmingham family support	0	5,359	0	5,359
Laboratory committee research	0	3,000	(474)	2,526
Total	46,572	276,695	(271,131)	52,136

HYPERLIPIDAEMIA EDUCATION AND RESEARCH TRUST UK

(A Company Limited by Guarantee)

NOTES TO THE FINANCIAL STATEMENTS

FOR THE YEAR ENDED 30 APRIL 2005

The Audrey Brent Memorial Fund represents monies which may be used to publish the Charity's annual lecture in the Digest.

The Simon Broome fund is for research into familial hyperlipidaemia family tracing through its own register of patients.

The other funds represent specific donations to fund the costs of lipid clinics, the help line and nursing training.

15. UNRESTRICTED FUNDS

	Group 2005	Charity 2005	Group 2004	Charity 2004
	£	£	as restated £	as restated £
Original balance brought forward	104,143	101,443	119,093	116,312
Prior year adjustment	(22,683)	(24,163)	0	0
Restated balance brought forward	81,460	77,280	119,093	116,312
Retained (loss)/profit	(32,673)	(32,835)	(37,633)	(39,032)
As at 30 April 2005	48,787	44,445	81,460	77,280

16. ANALYSIS OF GROUP NET ASSETS BETWEEN FUNDS

	General Fund	Restricted Funds	Total
	£	£	£
Fixed assets	6,256	0	6,256
Cash at bank and in hand	21,640	52,136	73,776
Other current assets	234,654	0	234,654
Current liabilities	(213,763)	0	(213,763)
	48,787	52,136	100,923

17. RELATED PARTIES

Exemption from disclosing transactions with other group companies has been claimed, as the trading subsidiary is wholly owned and included in these consolidated financial statements which are publicly available.